# Immune Modulation During Palynziq® Treatment in Adults (IMPALA)

> **NCT07477691** · PHASE4 · NOT_YET_RECRUITING · sponsor: **BioMarin Pharmaceutical** · enrollment: 12 (estimated)

## Conditions studied

- Phenylketonuria

## Interventions

- **BIOLOGICAL:** Pegvaliase
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT07477691
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07477691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07477691, "Immune Modulation During Palynziq® Treatment in Adults (IMPALA)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07477691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*